Science Pool

BMS-986094 (INX-08189) is a guanosine nucleotide analogue prodrug which was developed to treat hepatitis C virus (HCV). However, BMS-986094 was discontinued in Phase III clinical trials with 1 death and 8 people hospitalised with significantly reduced left ventricular ejection fraction (LVEF). Cardiotoxic effects were observed in 14 out of the 34 patients with left ventricular dysfunction, with ST depressions, T-wave inversions or loss of T-wave amplitude.

In this poster, we focus on:

• investigating the mechanism behind the cardiotoxicity of BMS-986094
• the use of MEA and human iPSC-derived cardiomyocytes in long term incubations with BMS-986094

Read our poster to learn more about our research!

LEARN MORE

In vitro 3D microtissue models are transforming our understanding of cardiotoxicity.

In this poster, we focus on:

• the use of a 3D cardiac triculture model consisting of iPSC-derived cardiomyocytes, cardiovascular endothelial cells and cardiac fibroblasts in cardiotoxicity prediction
• the detection of functional and structural mechanisms of cardiotoxicity
• calcium flux as a sensitive detection method for cardiac contraction as well as microtissue area for identifying cardiac hypertrophy
• HCS detection of cell health markers such as mitochondrial function, calcium homeostasis and nuclei/DNA structure

Read our poster to learn more about our research!

LEARN MORE